TY - JOUR
T1 - The state of Melanoma
T2 - Emergent challenges and opportunities
AU - Melanoma Research Foundation
AU - Atkins, Michael B.
AU - Curiel-Lewandrowski, Clara
AU - Fisher, David E.
AU - Swetter, Susan M.
AU - Tsao, Hensin
AU - Aguirre-Ghiso, Julio A.
AU - Soengas, Maria S.
AU - Weeraratna, Ashani T.
AU - Flaherty, Keith T.
AU - Herlyn, Meenhard
AU - Sosman, Jeffrey A.
AU - Tawbi, Hussein A.
AU - Pavlick, Anna C.
AU - Cassidy, Pamela B.
AU - Chandra, Sunandana
AU - Chapman, Paul B.
AU - Daud, Adil
AU - Eroglu, Zeynep
AU - Ferris, Laura K.
AU - Fox, Bernard A.
AU - Gershenwald, Jeffrey E.
AU - Gibney, Geoffrey T.
AU - Grossman, Douglas
AU - Hanks, Brent A.
AU - Hanniford, Douglas
AU - Hernando, Eva
AU - Jeter, Joanne M.
AU - Johnson, Douglas B.
AU - Khleif, Samir N.
AU - Kirkwood, John M.
AU - Leachman, Sancy A.
AU - Mays, Darren
AU - Nelson, Kelly C.
AU - Sondak, Vernon K.
AU - Sullivan, Ryan J.
AU - Merlino, Glenn
N1 - Funding Information:
The authors are indebted to Dr. Robyn Burns, Science Officer for the Melanoma Research Foundation, for her expert assistance with the preparation of this article. Research reported in this publication was supported, in part, by the NIH SPORE grants (1P50CA221703 to J.E. Gershenwald and P50CA225450 to E. Hernando), DoD/CDMRP Team Science Award (CA170374 to J.E. Gershenwald), the Robert and Lynne Grossman Family Foundation (to J.E. Gershenwald), the Michael and Patricia Booker Melanoma Research Endowment (to J.E. Gershenwald), philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson (to J.E. Gershenwald), NIH intramural research program (ZIABC008756 to G. Merlino), the InterMEL P01 (P01CA206980 to E. Hernando), and the Melanoma Research Foundation.
Funding Information:
M.B. Atkins reports grants and personal fees from BMS, Merck, and Pfizer, personal fees from Novartis, Genentech/Roche, personal fees from Eisai, Exe-lixis, AstraZeneca, Agenus, Adagene, Aveo, Array, Pyxis Oncology, Leads BioPharma, Werewolf, Elpis, TRV, PACT, Iovance, Idera, and Apexigen, personal fees and other from Arrowhead, Neoleukin, and Immunocore outside the submitted work, and stock options from Werewolf and Pyxis Oncology. C. Curiel-Lewandrowski reports personal fees from BMS and Helssin’s Pharm outside the submitted work. D.E. Fisher reports personal fees from Soltego and grants from NIH during the conduct of the study, as well as a patent for small-molecule regulators of pigmentation pending and licensed to Soltego Inc. H. Tsao reports personal fees from Epiphany Dermatology, Ortho Dermatolo-gics, and Up-to Date outside the submitted work. J.A. Aguirre-Ghiso is a scientific cofounder of, scientific advisory board member, and equity owner in HiberCell and receives financial compensation as a consultant for HiberCell, a Mount Sinai spin-off company focused on the research and development of therapeutics that prevent or delay the recurrence of cancer. M.S. Soengas reports other from Bioncotech Therapeutics outside the submitted work. A.T. Weerar-atna reports grants from NCI during the conduct of the study. K.T. Flaherty reports personal fees from Clovis Oncology, Strata Oncology, Checkmate Pharmaceuticals, Kinnate, Scorpion, PIC Therapeutics, Apricity, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Lilly, Takeda, Boston Biomedical, and X4 Pharmaceuticals and grants and personal fees from Novartis during the conduct of the study. J.A. Sosman reports personal fees from Array, Bristol Myers Squibb, Genentech, Iovance, and Apexigen, and grants from Bristol Myers Squibb outside the submitted work. H.A. Tawbi reports grants and personal fees from BMS, Merck, Novartis, Genentech, grants from GlaxoSmithKline, and personal fees from Iovance and Eisai outside the submitted work. A.C. Pavlick reports personal fees from BMS and Regeneron outside the submitted work. S. Chandra reports other from Bristol Myers Squibb, Novartis, Regeneron/Sanofi, Pfizer, EMD Serono, and Exicure outside the submitted work. P.B. Chapman reports personal fees from Merck and Pfizer during the conduct of the study. A. Daud reports grants from Merck, BMS, OncoSec, Incyte, Xencor, and Novartis, personal fees from Pfizer, Trex, and Neuvogen, and grants and personal fees from Genentech/Roche outside the submitted work. Z. Eroglu reports personal fees from Array, grants and personal fees from Novartis, personal fees from Genentech, Regeneron, Sun Pharma, and Natera outside the submitted work. L.K. Ferris reports personal fees from Derm Tech outside the submitted work. B.A. Fox reports personal fees and nonfinancial support from AstraZeneca, personal fees from Boehringer Ingelheim, CellDex Therapeutics, Definiens, PrimeVax, and Ultivue, grants and nonfinancial support from Bristol Myers Squibb, OncoSec, and Shimadzu, grants from Incyte, Janssen/
Publisher Copyright:
© American Association for Cancer Research.
PY - 2021/5
Y1 - 2021/5
N2 - Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
AB - Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
UR - http://www.scopus.com/inward/record.url?scp=85106306069&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-4092
DO - 10.1158/1078-0432.CCR-20-4092
M3 - Article
C2 - 33414132
AN - SCOPUS:85106306069
SN - 1078-0432
VL - 27
SP - 2678
EP - 2697
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -